

Providing answers for  
cancer patients

curasight



# Curasight A/S Interim report Q1 2026

In this document, the following definitions shall apply unless otherwise specified: "the Company" or "Curasight" refers to Curasight A/S, CVR no. 35249389.

The Company  
 CURASIGHT A/S  
 Ole Maaløes Vej 3  
 2200 København N  
 Tel.: 22 83 01 60  
 Registered office: København N  
 CVR no.: 35 24 93 89  
 Financial year: 01.01 - 31.12

## Key figures and selected posts

### Q1 (2026-01-01 – 2026-03-31)

- Gross loss amounted to kDKK -13,078 (kDKK -4,699)
- Operating loss amounted to kDKK -15,278 (kDKK -6,209)
- Loss before tax amounted to kDKK -16,704 (kDKK -6,579)
- Loss for the period amounted to kDKK -15,329 (kDKK -5,204)
- Total assets amounted to kDKK 36,246 (kDKK 17,660)
- Equity ratio amounted to 19.0% (14.2%)
- Earnings per share amounted to DKK -0.32 (DKK -0.25)

Numbers in parenthesis are the numbers from the same period in 2025.

#### Definitions

Equity ratio: Shareholders equity as a proportion of total assets.  
 Earnings per share: Profit/Loss for the period divided by average number of shares.

# Advancing toward key milestones

**The first quarter of 2026 marked continued progress for Curasight as we advanced our uPAR-targeted theranostic platform and strengthened the Company's strategic and financial foundation.**

Most importantly, in January we announced encouraging preliminary data from our ongoing Phase 1 trial evaluating uTREAT® in patients with high-grade gliomas. We firmly believe that our radiopharmaceutical uTREAT therapy can offer an important differentiated new treatment option for certain cancers and this study in aggressive brain cancer will pave the way for further development in areas of significant unmet medical needs.

At the same time during the quarter we continued to advance our diagnostic platform, uTRACE®. The progress being made with both our therapeutic arm uTREAT and uTRACE illustrates the strength of our integrated theranostic strategy using uPAR imaging to both diagnose and treat the cancer - "What you see is what you treat." We remain focused on disciplined clinical execution while preparing for the next important value inflection points across both programs.

During the quarter, we also strengthened our Board of Directors with the appointment of two highly experienced international healthcare industry profiles, Marcel Reichen and Colin Hayward. Marcel Reichen brings extensive global pharmaceutical leadership experience, including senior leadership roles at Novartis, where he was closely involved in the commercialization and strategic development of advanced oncology and radioligand therapy programs. Colin Hayward contributes deep expertise within the radiopharmaceutical and radionuclide therapy (RLT) field through his experience at Telix and other companies active in targeted radiopharmaceutical development and commercialization. Together, they bring highly relevant competencies spanning radioligand therapy strategy, clinical development, regulatory pathways, manufacturing, commercialization, and global partnering within the rapidly growing theranostics market. We believe their combined strategic, commercial, and industry experience will provide valuable support as Curasight advances its clinical programs and continues to strengthen its international positioning within targeted radionuclide therapy and precision oncology.

During the quarter, we also continued to increase Curasight's visibility within the international healthcare and investor communities. In January, we participated in the J.P. Morgan Healthcare Conference Week, one of the most important global life science industry events, and in March we presented at TD Cowen's 46th Annual Health Care Conference in Boston. These activities provided valuable opportunities to engage with potential partners, investors, and industry stakeholders as interest in targeted radiopharmaceutical therapies continues to grow globally.

From a financial perspective, we also continued to ensure our financial foundation when in March we completed a partial conversion of the Company's convertible loan with Fenja Capital. The transaction reduced debt while simultaneously broadening our long-term shareholder base through the subsequent placement of converted shares with a consortium of long-term investors at a premium to the conversion price. We view the partial conversion of the loan by Fenja as validation of the Company's strategic direction and future potential.

Looking ahead, we expect several important milestones and news flow during rest of 2026. Our primary focus remains on advancing the clinical development of uTREAT® and uTRACE®, including continued patient enrollment, additional clinical data generation, and preparations for the next stages of development across our programs.

We also anticipate increasing strategic and commercial interest in the radiopharmaceutical field, where recent industry developments continue to validate the significant market potential of targeted theranostics. Curasight remains well positioned to participate in this momentum, and we look forward to updating the market on our clinical progress and strategic initiatives throughout the coming quarters.

I would like to thank our shareholders, employees, clinical collaborators, and partners for their continued support and dedication.

Sincerely,

**Ulrich Krasilnikoff**  
 CEO, Curasight A/S

# Highlights during first quarter and after the peiord

**On January 5,** announced that Curasight participated at the J.P. Morgan Healthcare Conference Week.

**On January 12,** announced encouraging preliminary data from Phase 1 Trial evaluating First-in-Class radiopharmaceutical uTREAT® in high-grade gliomas.

**On February 17,** announced that Curasight will present at TD Cowen's 46th Annual Health Care Conference in Boston.

**On March 6,** completed a partial conversion of its DKK 25 million convertible loan with Fenja Capital, resulting in the issuance of 429,363 new shares corresponding to approximately DKK 4.3 million at a conversion price of DKK 9.975 per share. The converted shares were subsequently sold by Fenja Capital to a consortium of long-term investors at DKK 15.75 per share.

**On April 26,** announced an internal ownership restructuring in which co-founders Andreas Kjær and Ulrich Krasilnikoff consolidated their holdings into the jointly controlled company Curacap II ApS. Following the transaction, Curacap II ApS holds 13,695,001 shares, corresponding to 28.33% of the shares and voting rights in Curasight. The restructuring is technical in nature and does not affect the Company's operations, strategy, financial position, or ultimate ownership control.



By combining diagnostics with therapy – Curasight is on a mission to improve the lives of millions of people with cancer

# Curasight A/S in short

Curasight A/S is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors.

The therapeutic platform uTREAT® is validated and supported by uTRACE®, a clinically validated uPAR PET imaging agent built on the same targeting ligand, enabling one-to-one patient selection and biodistribution confirmation under a disciplined theranostic approach.

uTRACE® has been evaluated in nine clinical studies in more than 450 patients across eight solid tumor types, providing a substantial human imaging evidence base for uPAR target engagement and ligand performance. uTRACE® is a fully developed companion diagnostics for uTREAT(R).

## The scientific rationale – why uPAR?

uPAR (urokinase-type plasminogen activator receptor) is associated with tumor invasion, angiogenesis, and metastasis and is considered a functional driver of cancer aggressiveness. Curasight's thesis is that uPAR can be used as an "address label" to deliver targeted radiation to clinically relevant tumor biology, rather than attempting to inhibit uPAR signaling through conventional drug modalities.

Rather than being limited to a single tumor type, uPAR is broadly expressed across solid tumors.

This makes uPAR a scalable therapeutic target across multiple aggressive tumor types.

Historically, uPAR has been difficult to exploit using conventional drug modalities. Radioligand therapy uTREAT® reframes the opportunity: instead of blocking uPAR signaling, the receptor can be used as a handle to deliver a payload of radiation directly to aggressive cancer cells and eliminate them.

## uPAR Theranostic

The combination of non-invasive PET imaging (Diagnostic) and uPAR targeted radioligand therapy (Therapy) is together known as Theranostics and where uTRACE® serves as a companion diagnostics for uTREAT®.

## (Therapy) uTREAT®

uPAR-targeted radioligand therapy (RLT) designed to deliver a radioactive payload to uPAR-expressing tumor tissue.

## (Diagnostics) uTRACE®

uPAR PET imaging with uTRACE® for improved imaging of cancer across several cancer types and patient selection and biodistribution confirmation.

## Pipeline and clinical focus

**uTREAT®:** Curasight's lead asset is uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors. In December 2025 the first patient was dosed in Curasights Phase 1 trial in glioblastoma (GBM), an aggressive brain cancer with high unmet medical need. The program is designed to generate quantitative insights on biodistribution and dosimetry that can guide subsequent clinical decisions and potential platform expansion. Top line data is expected mid-2026.

Following proof-of-concept in GBM, and subject to clinical data, regulatory feedback and available resources, Curasight intends to evaluate uTREAT® in additional uPAR-expressing solid tumors and may use basket-style clinical strategies to support disciplined indication selection. Indications under consideration include non-small cell lung cancer (NSCLC), neuroendocrine tumors (NET), head and neck cancer, pancreatic cancer, and colorectal cancer.

**uTRACE® (imaging)** is a supporting asset and operational enabler for the platform. In prostate cancer, uTRACE® is being evaluated under a collaboration signed in 2023 with Curium Pharma. Curasight leads the program and retains all rights to uTREAT® and uTRACE® outside prostate cancer.

**Next-generation uPAR ligands:** In parallel, Curasight is advancing next-generation uPAR ligands (higher-affinity linear and macrocyclic peptide binders) intended to support future platform expansion and improve uptake at lower target density. Development timelines remain subject to progress.

**GMP Manufacturing:** Radiopharmaceutical development requires robust clinical and manufacturing execution. Curasight's platform benefits from GMP experience established through uTRACE® clinical use and from a shared ligand strategy across imaging and therapy, which reduces complexity and supports reproducible workflows as clinical development progresses.

## The RLT Market

Established theranostic pathways such as PSMA and SSTR2 demonstrate that disciplined target selection, patient stratification and dosimetry driven RLT can create meaningful clinical and economic impact.

Curasights uPAR platform differentiates from marketed RLT's in that it holds the potential to enable one drug to become a therapy for multiple aggressive tumor types. The theranostic approach makes it highly specific and personalized.

## Key facts

- Lead value driver: uTREAT® (uPAR-targeted RLT) – Phase 1 initiated in GBM; first patient dosed in December 2025.
- Supporting asset: uTRACE® (uPAR PET imaging) – evaluated in nine clinical studies (>450 patients) across eight solid tumor types; Phase 2 in prostate cancer led by Curium (collaboration signed in 2023).
- Platform thesis: one target (uPAR) and one targeting ligand enabling therapy-led development with imaging support for patient selection and biodistribution confirmation.
- Scientific origin: based on research conducted at Rigshospitalet and the University of Copenhagen led by Professor Andreas Kjær and collaborators.
- Intellectual property: patent portfolio and pending applications reported by the Company to extend to 2043.

## Important information

uTREAT® is an investigational compound. Its safety and efficacy have not yet been established and it has not been approved by any regulatory authority. This section may contain forward-looking statements, including statements regarding clinical development plans and timing; actual results may differ materially due to risks and uncertainties.

## About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Approximately 65,000 patients in the US and EU are diagnosed annually with brain tumors of which approximately 30,000 patients are diagnosed with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, drug candidates are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

## About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with

the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body.

## About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years.

## About Non Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies.

## About Pancreatic Cancer

Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024.


## About Prostate cancer

Prostate cancer is the most common cancer in men, with approximately 640,000 new cases expected to be diagnosed annually across the US and the EU. While many tumors grow slowly, a significant proportion develop into aggressive disease that is challenging to detect and monitor with existing methods. Accurate detection and monitoring of prostate cancer remain major challenges, particularly in patients with advanced or recurrent disease.

## About colorectal cancer

Colorectal cancer (CRC) is among the most common malignancies and remains a major cause of cancer mortality. Approximately ~670,000 patients are diagnosed each year across the US and Europe. Despite effective screening in parts of the population, a substantial fraction of patients are still diagnosed with advanced disease; in the US the overall 5-year relative survival is ~63%, dropping to ~13% for distant (metastatic) disease, underscoring the need for more effective treatments for advanced CRC.


# Key clinical milestones 2025-2026



# Therapeutic Program



Sponsor: Curasight  
 Diagnostic platform: uTRACE® and uTREAT®



\*A basket trial is designed to simultaneously evaluate treatments for multiple tumors in a single clinical trial. Curasight will investigate cancer therapy with uTREAT® in selected cancer diseases known to express uPAR.

# Partnered Project



Sponsor: Curasight  
 Partner: Curium Inc.  
 Diagnostic platform: uTRACE®




\* Investigated for diagnostic performance for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer.  
 \*\* Investigator-initiated study



# Investigator Initiated Trials



Sponsor: National University Hospital of Denmark (Rigshospitalet)  
Diagnostic platform: uTRACE®



<sup>\*)</sup> Investigator Initiated Trails = IITs, >400 patients have received uTrace in these Investigator Initiated Trials  
<sup>\*\*)</sup> Completed with fewer patients than planned for technical reasons

# Financial analyst coverage



**Since:**  
June, 2021

**Type:**  
Commissioned

**Frequency:**  
Continuously

**Areas:**  
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

**Since:**  
May, 2025

**Type:**  
Commissioned

**Frequency:**  
Continuously

**Areas:**  
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

**Since:**  
August, 2021

**Type:**  
Commissioned

**Frequency:**  
Continuously

**Areas:**  
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

# Corporate Information

## Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
Curacap ApS <sup>1</sup>	28.33
Madsen Holding 2013 ApS <sup>2</sup>	1.95
Kirsten Drejer <sup>3</sup>	0.12

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer and by CEO and Board Member Ulrich Krasilnikoff

2. Owned by Co-founder and Director CMC, Jacob Madsen

3. Chair of the Board of Directors

## The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020. The short name/ticker is CURAS, and the ISIN code is DK0061295797. As of March 31, 2026, the number of shares was 48,352,204 (21,148,880). All shares have equal rights to the Company's assets and results.

## Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (former dept. chairman of the Board of Directors), Charlotte Vedel (former member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoff (CEO), Andreas Kjær (CSO), Hanne Damgaard Jensen (former COO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

On July 30, 2024, Curasight re-issued a total of 59,132 (previously lapsed) warrants with rights to subscribe for a total of DKK 2,956.60 nominally worth of shares in the Company. 42,460 warrants has been re-issued as part of the ordinary incentive program covering the Executive Management and key employees of the Company. 16,672 warrants has been re-issued and allocated to Chair of the Board of Directors Kirsten Drejer as part of the ordinary incentive program covering the Board of

Directors of the Company.

## Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the disclosure document published by the Company in 2025. The document is available on Curasight's website: [www.curasight.com/investor/rights-issue-2025](http://www.curasight.com/investor/rights-issue-2025).

## Accounting policy

The interim report is presented in accordance with the provisions of the Danish Financial Statements Act (Årsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.

## Auditor's review

The interim report has not been reviewed by the Company's auditor.

## Financial calendar

Interim report Q2 2026	August 27, 2026
Interim report Q3 2026	November 26, 2026

# Financial statements

## Income statement

Operating loss before tax for the first quarter of 2026 amounted to kDKK -16,704 (kDKK -6,579). Operating loss before tax for 2025 amounted to kDKK -15,278 (kDKK -6,209).

Loss before depreciation, amortisation and impairments for the first quarter amounted to kDKK -15,074 (kDKK -6,006) of which staff expenses was kDKK -1,996 (kDKK -1,307).

Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses.

## Balance sheet

Per March 31, 2026, the Company's balance sheet amounted to kDKK 36,246 (17,660).

The assets consisted primarily of acquired IP-rights totaling kDKK 5,810 related to the development of uTRACE® and uTREAT®, total receivables of kDKK 8,271 and cash amounted to kDKK 22,089. The equity and liabilities consisted primarily of an equity totaling kDKK 6,892 and short-term debt of kDKK 29,354 which primarily consisted of the drawn credit facility of kDKK 22,150 (kDKK 12,134).

## Cash flow

Curasight's total cash flow in Q1 2026 amounted to kDKK -13,824. Curasight's cash flow from operating activities in January – March 2025 amounted to kDKK -19,001.

Cash as of March 31, 2026, was kDKK 22,088 (kDKK 1,514).



## Income statement

(kDKK)	Q1 2026*	Q1 2025*	Q1-Q4 2025
<b>Gross loss</b>	<b>-13,078</b>	<b>-4,699</b>	<b>-49,676</b>
Staff expenses	-1,996	-1,307	-5,102
<b>Loss before depreciation, amortisation, write-downs and impairment losses</b>	<b>-15,074</b>	<b>-6,006</b>	<b>-54,778</b>
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-203	-204	-814
<b>Operating loss</b>	<b>-15,278</b>	<b>-6,209</b>	<b>-55,592</b>
Net financial income	-1,426	-370	42
Net financial expenses	-1,426	-370	-3,180
<b>Loss before tax</b>	<b>-16,704</b>	<b>-6,579</b>	<b>-58,730</b>
Tax on loss for the period	1,375	1,375	5,500
<b>Loss for the period</b>	<b>-15,329</b>	<b>-5,204</b>	<b>-53,230</b>

\*) Unaudited figures

## Balance sheet, Assets

(kDKK)	2026-03-31	2025-03-31	2025-12-31
Acquired patents	5,810	6,624	6,013
<b>Intangible assets</b>	<b>5,810</b>	<b>6,624</b>	<b>6,013</b>
Deposits	77	51	77
<b>Total investments</b>	<b>77</b>	<b>51</b>	<b>77</b>
<b>Total non-current assets</b>	<b>5,887</b>	<b>6,675</b>	<b>6,090</b>
Other receivables	1,396	2,596	2,553
Income tax receivables	6,875	6,875	5,500
<b>Total receivables</b>	<b>8,271</b>	<b>9,471</b>	<b>8,053</b>
Cash at bank and in hand	22,089	1,514	35,912
<b>Total current assets</b>	<b>30,359</b>	<b>10,985</b>	<b>43,965</b>
<b>Assets</b>	<b>36,246</b>	<b>17,660</b>	<b>50,055</b>

## Balance sheet—Liabilities and equity

(kDKK)	2026-03-31	2025-03-31	2025-12-31
Share capital	2,418	1,057	2,396
Retained earnings	4,474	1,450	15,540
<b>Equity</b>	<b>6,892</b>	<b>2,507</b>	<b>17,936</b>
Trade payables	7,204	3,019	6,123
Other payables	22,150	12,134	25,996
<b>Short term-debt</b>	<b>29,354</b>	<b>15,153</b>	<b>32,119</b>
<b>Debt</b>	<b>29,354</b>	<b>15,153</b>	<b>32,119</b>
<b>Liabilities and equity</b>	<b>36,246</b>	<b>17,660</b>	<b>50,055</b>

## Equity—Q1\* 2026

(kDKK)	Share capital	Share account premium	Retained earnings	Total
<b>Change in equity Q1 2026</b>				
Equity at 1 January 2026	2,396	0	15,540	17,936
Net profit/loss for the year	22	0	-11,066	-11,044
<b>Equity at 31 March 2026</b>	<b>2,418</b>	<b>0</b>	<b>4,474</b>	<b>6,892</b>

\*) Unaudited figures

## Equity—Q1\* 2025

(kDKK)	Share capital	Share account premium	Retained earnings	Total
<b>Change in equity: Q1 2025</b>				
Equity at 1 January 2025	1,057	0	6,654	7,711
Net profit/loss for the period	0	0	-5,204	-5,204
<b>Equity at 31 March 2025</b>	<b>1,057</b>	<b>0</b>	<b>1,450</b>	<b>2,507</b>

## Equity—FY 2025

(kDKK)	Share capital	Share account premium	Retained earnings	Total
<b>Change in equity: Q1-Q4 2025</b>				
Equity at 1 January 2025	1,057	0	6,654	7,711
Net profit/loss for the year	0	0	-53,230	-53,230
Capital Increase	1,339	0	62,116	63,455
<b>Equity at 31 December 2025</b>	<b>2,396</b>	<b>0</b>	<b>15,540</b>	<b>17,936</b>

\*) Unaudited figures

## Cash flow statement

(kDKK)	Q1 2026*	Q1 2025*	Q1-Q4 2025
<b>Loss for the period</b>	<b>-15,329</b>	<b>-5,204</b>	<b>-53,230</b>
Adjustments	-2,982	-2,256	-1,506
Change in working capital	739	-997	-
<b>Cash flow from operating activities before net financials</b>	<b>-17,572</b>	<b>-8,458</b>	<b>-54,079</b>
Interest expenses and similar expenses paid	-1,428	-370	-3,139
Income tax received/paid	0	0	5,500
<b>Cash flow from operating activities</b>	<b>-19,001</b>	<b>-8,828</b>	<b>-51,718</b>
Change in deposits	77	331	26
Proceeds from loans	5,100	0	14,138
Capital increase	0	0	63,455
<b>Cash flows from investing activities</b>	<b>5,177</b>	<b>331</b>	<b>77,619</b>
<b>Total cash flows for the period</b>	<b>-13,824</b>	<b>-8,497</b>	<b>25,901</b>
Cash, beginning of the period	35,912	10,011	10,011
<b>Cash, end of the period</b>	<b>22,088</b>	<b>1,514</b>	<b>35,912</b>
Cash, end of the period	<b>22,088</b>	<b>1,514</b>	<b>35,912</b>
<b>Total</b>	<b>22,088</b>	<b>1,514</b>	<b>35,912</b>

\*) Unaudited figures

## Statement by the Board of Directors

The Board of Directors provide their assurance that the interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, May 28, 2026  
Curasight A/S

### Board of Directors

Kirsten Drejer  
*Chair of the Board*

Andreas Kjær  
*Dept. chair of the Board*

Marcel Reichen  
*Board member*

Colin Hayward  
*Board member*

Ulrich Krasilnikoff  
*Board member and CEO*

**Curasight's team are pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT<sup>®</sup> radiation therapy, with the precise uTRACE<sup>®</sup> diagnostics.**